In the present study, inhibitors of both p38 and STAT1 could reduce the induction of iNOS expression and NO production in RASMCs caused by CMS, suggesting that both factors were involved in CMS-mediated iNOS-NO signaling. This evidence concerns the gene MAPK14 and congenital myasthenic syndrome.